Global Molecular Pharming Market Research Report 2025

Publication ID:

PB504250461

Publication Date:

April 28, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Molecular Pharming was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Molecular pharming, also known as biopharming, is a technology that involves the use of genetically modified plants to produce pharmaceuticals or industrial chemicals. This approach relies on the ability of plants to serve as bioreactors for the production of proteins and other complex molecules.
To produce a desired protein, the gene encoding the protein is first inserted into the plant genome. The plant is then grown under controlled conditions, and the protein is harvested from the plant tissue. The protein can then be purified and used for a variety of applications, including drug development, vaccines, and enzyme replacement therapies.
Molecular pharming has several advantages over traditional methods of protein production. Plants are relatively easy to grow and require minimal processing, which can result in lower production costs. Additionally, plant-based production systems are considered to be safer than those that use animal cells or bacteria, as plants are less likely to transmit viruses or other contaminants.
Despite its potential benefits, molecular pharming also has some limitations and challenges. One of the main challenges is ensuring that the plant-produced proteins are properly folded and functional, which can be influenced by factors such as post-translational modifications, environmental conditions, and the choice of plant species. Additionally, there are regulatory and ethical considerations associated with using genetically modified plants for pharmaceutical production.
North American market for Molecular Pharming is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Molecular Pharming is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Molecular Pharming in Recombinant Antibodies is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Molecular Pharming include Medicago Inc, Meristem Therapeutics S.A. (Ventria Bioscience), Miruku, Moolec Science Limited, mozza, Nobell Foods, Agrenvec S.L, Bright Biotech, Core Biogenesis, Diamante SRL, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Molecular Pharming, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Molecular Pharming.
The Molecular Pharming market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Molecular Pharming market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Molecular Pharming companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medicago Inc
Meristem Therapeutics S.A. (Ventria Bioscience)
Miruku
Moolec Science Limited
mozza
Nobell Foods
Agrenvec S.L
Bright Biotech
Core Biogenesis
Diamante SRL
Leaf Systems International Limited
ORF Genetics
Pfizer, Inc.
ProdiGene Inc
Protalix Biotherapeutics, Inc
Tiamat Sciences
Segment by Type
Gene Gun
Agroinfiltration
Electroporation
Agrobacterium-Mediated Gene Transfer
Segment by Application
Recombinant Antibodies
Hormones, Vaccines
Industrial Enzymes
Proteins & Protein-Based Materials
Technical Reagents
Nutritional Products
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Molecular Pharming company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Molecular Pharming Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Gene Gun
1.2.3 Agroinfiltration
1.2.4 Electroporation
1.2.5 Agrobacterium-Mediated Gene Transfer
1.3 Market by Application
1.3.1 Global Molecular Pharming Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Recombinant Antibodies
1.3.3 Hormones, Vaccines
1.3.4 Industrial Enzymes
1.3.5 Proteins & Protein-Based Materials
1.3.6 Technical Reagents
1.3.7 Nutritional Products
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Molecular Pharming Market Perspective (2020-2031)
2.2 Global Molecular Pharming Growth Trends by Region
2.2.1 Global Molecular Pharming Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Molecular Pharming Historic Market Size by Region (2020-2025)
2.2.3 Molecular Pharming Forecasted Market Size by Region (2026-2031)
2.3 Molecular Pharming Market Dynamics
2.3.1 Molecular Pharming Industry Trends
2.3.2 Molecular Pharming Market Drivers
2.3.3 Molecular Pharming Market Challenges
2.3.4 Molecular Pharming Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Molecular Pharming Players by Revenue
3.1.1 Global Top Molecular Pharming Players by Revenue (2020-2025)
3.1.2 Global Molecular Pharming Revenue Market Share by Players (2020-2025)
3.2 Global Molecular Pharming Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Molecular Pharming Revenue
3.4 Global Molecular Pharming Market Concentration Ratio
3.4.1 Global Molecular Pharming Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Molecular Pharming Revenue in 2024
3.5 Global Key Players of Molecular Pharming Head office and Area Served
3.6 Global Key Players of Molecular Pharming, Product and Application
3.7 Global Key Players of Molecular Pharming, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Molecular Pharming Breakdown Data by Type
4.1 Global Molecular Pharming Historic Market Size by Type (2020-2025)
4.2 Global Molecular Pharming Forecasted Market Size by Type (2026-2031)
5 Molecular Pharming Breakdown Data by Application
5.1 Global Molecular Pharming Historic Market Size by Application (2020-2025)
5.2 Global Molecular Pharming Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Molecular Pharming Market Size (2020-2031)
6.2 North America Molecular Pharming Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Molecular Pharming Market Size by Country (2020-2025)
6.4 North America Molecular Pharming Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Molecular Pharming Market Size (2020-2031)
7.2 Europe Molecular Pharming Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Molecular Pharming Market Size by Country (2020-2025)
7.4 Europe Molecular Pharming Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Molecular Pharming Market Size (2020-2031)
8.2 Asia-Pacific Molecular Pharming Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Molecular Pharming Market Size by Region (2020-2025)
8.4 Asia-Pacific Molecular Pharming Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Molecular Pharming Market Size (2020-2031)
9.2 Latin America Molecular Pharming Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Molecular Pharming Market Size by Country (2020-2025)
9.4 Latin America Molecular Pharming Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Molecular Pharming Market Size (2020-2031)
10.2 Middle East & Africa Molecular Pharming Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Molecular Pharming Market Size by Country (2020-2025)
10.4 Middle East & Africa Molecular Pharming Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medicago Inc
11.1.1 Medicago Inc Company Details
11.1.2 Medicago Inc Business Overview
11.1.3 Medicago Inc Molecular Pharming Introduction
11.1.4 Medicago Inc Revenue in Molecular Pharming Business (2020-2025)
11.1.5 Medicago Inc Recent Development
11.2 Meristem Therapeutics S.A. (Ventria Bioscience)
11.2.1 Meristem Therapeutics S.A. (Ventria Bioscience) Company Details
11.2.2 Meristem Therapeutics S.A. (Ventria Bioscience) Business Overview
11.2.3 Meristem Therapeutics S.A. (Ventria Bioscience) Molecular Pharming Introduction
11.2.4 Meristem Therapeutics S.A. (Ventria Bioscience) Revenue in Molecular Pharming Business (2020-2025)
11.2.5 Meristem Therapeutics S.A. (Ventria Bioscience) Recent Development
11.3 Miruku
11.3.1 Miruku Company Details
11.3.2 Miruku Business Overview
11.3.3 Miruku Molecular Pharming Introduction
11.3.4 Miruku Revenue in Molecular Pharming Business (2020-2025)
11.3.5 Miruku Recent Development
11.4 Moolec Science Limited
11.4.1 Moolec Science Limited Company Details
11.4.2 Moolec Science Limited Business Overview
11.4.3 Moolec Science Limited Molecular Pharming Introduction
11.4.4 Moolec Science Limited Revenue in Molecular Pharming Business (2020-2025)
11.4.5 Moolec Science Limited Recent Development
11.5 mozza
11.5.1 mozza Company Details
11.5.2 mozza Business Overview
11.5.3 mozza Molecular Pharming Introduction
11.5.4 mozza Revenue in Molecular Pharming Business (2020-2025)
11.5.5 mozza Recent Development
11.6 Nobell Foods
11.6.1 Nobell Foods Company Details
11.6.2 Nobell Foods Business Overview
11.6.3 Nobell Foods Molecular Pharming Introduction
11.6.4 Nobell Foods Revenue in Molecular Pharming Business (2020-2025)
11.6.5 Nobell Foods Recent Development
11.7 Agrenvec S.L
11.7.1 Agrenvec S.L Company Details
11.7.2 Agrenvec S.L Business Overview
11.7.3 Agrenvec S.L Molecular Pharming Introduction
11.7.4 Agrenvec S.L Revenue in Molecular Pharming Business (2020-2025)
11.7.5 Agrenvec S.L Recent Development
11.8 Bright Biotech
11.8.1 Bright Biotech Company Details
11.8.2 Bright Biotech Business Overview
11.8.3 Bright Biotech Molecular Pharming Introduction
11.8.4 Bright Biotech Revenue in Molecular Pharming Business (2020-2025)
11.8.5 Bright Biotech Recent Development
11.9 Core Biogenesis
11.9.1 Core Biogenesis Company Details
11.9.2 Core Biogenesis Business Overview
11.9.3 Core Biogenesis Molecular Pharming Introduction
11.9.4 Core Biogenesis Revenue in Molecular Pharming Business (2020-2025)
11.9.5 Core Biogenesis Recent Development
11.10 Diamante SRL
11.10.1 Diamante SRL Company Details
11.10.2 Diamante SRL Business Overview
11.10.3 Diamante SRL Molecular Pharming Introduction
11.10.4 Diamante SRL Revenue in Molecular Pharming Business (2020-2025)
11.10.5 Diamante SRL Recent Development
11.11 Leaf Systems International Limited
11.11.1 Leaf Systems International Limited Company Details
11.11.2 Leaf Systems International Limited Business Overview
11.11.3 Leaf Systems International Limited Molecular Pharming Introduction
11.11.4 Leaf Systems International Limited Revenue in Molecular Pharming Business (2020-2025)
11.11.5 Leaf Systems International Limited Recent Development
11.12 ORF Genetics
11.12.1 ORF Genetics Company Details
11.12.2 ORF Genetics Business Overview
11.12.3 ORF Genetics Molecular Pharming Introduction
11.12.4 ORF Genetics Revenue in Molecular Pharming Business (2020-2025)
11.12.5 ORF Genetics Recent Development
11.13 Pfizer, Inc.
11.13.1 Pfizer, Inc. Company Details
11.13.2 Pfizer, Inc. Business Overview
11.13.3 Pfizer, Inc. Molecular Pharming Introduction
11.13.4 Pfizer, Inc. Revenue in Molecular Pharming Business (2020-2025)
11.13.5 Pfizer, Inc. Recent Development
11.14 ProdiGene Inc
11.14.1 ProdiGene Inc Company Details
11.14.2 ProdiGene Inc Business Overview
11.14.3 ProdiGene Inc Molecular Pharming Introduction
11.14.4 ProdiGene Inc Revenue in Molecular Pharming Business (2020-2025)
11.14.5 ProdiGene Inc Recent Development
11.15 Protalix Biotherapeutics, Inc
11.15.1 Protalix Biotherapeutics, Inc Company Details
11.15.2 Protalix Biotherapeutics, Inc Business Overview
11.15.3 Protalix Biotherapeutics, Inc Molecular Pharming Introduction
11.15.4 Protalix Biotherapeutics, Inc Revenue in Molecular Pharming Business (2020-2025)
11.15.5 Protalix Biotherapeutics, Inc Recent Development
11.16 Tiamat Sciences
11.16.1 Tiamat Sciences Company Details
11.16.2 Tiamat Sciences Business Overview
11.16.3 Tiamat Sciences Molecular Pharming Introduction
11.16.4 Tiamat Sciences Revenue in Molecular Pharming Business (2020-2025)
11.16.5 Tiamat Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

Medicago Inc
Meristem Therapeutics S.A. (Ventria Bioscience)
Miruku
Moolec Science Limited
mozza
Nobell Foods
Agrenvec S.L
Bright Biotech
Core Biogenesis
Diamante SRL
Leaf Systems International Limited
ORF Genetics
Pfizer, Inc.
ProdiGene Inc
Protalix Biotherapeutics, Inc
Tiamat Sciences

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂